Author

Nicholas Powell

Webinar | GI and liver complications of checkpoint inhibitors
Webinar | GI and liver complications of checkpoint inhibitors

Nicholas Powell  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Nicholas Powell  et al.

Item 1 - 2 / 2
1